secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001818331-24-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q4 revenue $58.1M (+27% YoY); exome/genome revenue up 68%; guides FY2024 $220-230M
--------------------------------------------------------------------------------

- Q4 revenue from continuing ops $58.1M (+27% YoY); exome/genome revenue $39.2M (+68% YoY).
- Adjusted gross margin expanded to 56% (from 41% Q4 2022); exome/genome margin >60%.
- Adjusted net loss narrowed to $17.8M, a 76% improvement YoY; cash burn reduced 51% YoY.
- FY2024 revenue guidance $220-230M; reiterates path to profitability in 2025.
- Exome/genome test volume 15,663 in Q4 (+99% YoY); 49,439 full year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/0001818331-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000006/wgs-20240220.htm
  HTML page:      https://secwatch.observer/filing/0001818331-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer